OBJECTIVE: Breast cancer (BC) diagnosis is a potentially traumatic event, the related challenges of which can trigger positive or negative reactions. Posttraumatic growth (PTG) is defined as a positive psychological change experienced as a result of the struggle. The present study aimed to shed light on the relationship between the evolution of depressive symptoms over time and PTG in a group of BC survivors. METHOD: Depressive symptoms at the time of diagnosis (T0) and 2 years later (T1) were evaluated to investigate their potential impact on the level of PTG at T1. A total of 147 BC patients were recruited and divided into 4 groups according to the changes in depressive symptoms they experienced over time (patients who were never depressed, no longer depressed, still depressed, and depressed now). A One-way analysis of variance was run to compare the levels of PTG for the four groups. RESULTS: The One-way analysis of variance showed that PTG score was significantly different among groups with different levels of depressive symptoms (p = .008). Post hoc comparisons indicated that the PTG score was statistically significantly higher in the no longer depressed group compared with the still depressed and depressed now groups. CONCLUSIONS: The current results suggest that high levels of depressive symptoms, displayed at the time of cancer diagnosis, can be considered catalysts for PTG at follow-up, on condition that women experience elevated depressive symptoms only in the first period of the disease. (PsycINFO Database Record (c) 2020 APA, all rights reserved).
OBJECTIVE:Breast cancer (BC) diagnosis is a potentially traumatic event, the related challenges of which can trigger positive or negative reactions. Posttraumatic growth (PTG) is defined as a positive psychological change experienced as a result of the struggle. The present study aimed to shed light on the relationship between the evolution of depressive symptoms over time and PTG in a group of BC survivors. METHOD:Depressive symptoms at the time of diagnosis (T0) and 2 years later (T1) were evaluated to investigate their potential impact on the level of PTG at T1. A total of 147 BC patients were recruited and divided into 4 groups according to the changes in depressive symptoms they experienced over time (patients who were never depressed, no longer depressed, still depressed, and depressed now). A One-way analysis of variance was run to compare the levels of PTG for the four groups. RESULTS: The One-way analysis of variance showed that PTG score was significantly different among groups with different levels of depressive symptoms (p = .008). Post hoc comparisons indicated that the PTG score was statistically significantly higher in the no longer depressed group compared with the still depressed and depressed now groups. CONCLUSIONS: The current results suggest that high levels of depressive symptoms, displayed at the time of cancer diagnosis, can be considered catalysts for PTG at follow-up, on condition that women experience elevated depressive symptoms only in the first period of the disease. (PsycINFO Database Record (c) 2020 APA, all rights reserved).
Authors: Rocío Guil; Lucia Morales-Sánchez; Paula Ruiz-González; Rocío Gómez-Molinero; Paloma Gil-Olarte Journal: Int J Environ Res Public Health Date: 2022-04-12 Impact factor: 4.614
Authors: Li Ping Wong; Lee Lee Lai; Mee Hoong See; Haridah Alias; Mahmoud Danaee; Chuo Yew Ting; Peter Seah Keng Tok Journal: Support Care Cancer Date: 2021-04-01 Impact factor: 3.359
Authors: Rocío Guil; Paula Ruiz-González; Lucía Morales-Sánchez; Rocío Gómez-Molinero; Paloma Gil-Olarte Journal: Int J Environ Res Public Health Date: 2022-07-14 Impact factor: 4.614